SG/CALL/STRYKER CORP./200/0.1/21.06.24 Share Price

Warrant

DE000SQ4HB82

Market Closed - Deutsche Boerse AG 20:35:56 31/05/2024 BST
12.74 EUR -1.85% Intraday chart for SG/CALL/STRYKER CORP./200/0.1/21.06.24
1 month-1.32%
3 months-9.00%
Date Price Change
31/05/24 12.74 -1.85%
30/05/24 12.98 -0.46%
29/05/24 13.04 +2.60%
28/05/24 12.71 +5.56%
27/05/24 12.04 -3.99%

Delayed Quote Deutsche Boerse AG

Last update May 31, 2024 at 08:35 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying STRYKER CORPORATION
IssuerLogo Issuer Société Générale Société Générale
WKN SQ4HB8
ISINDE000SQ4HB82
Date issued 16/11/2022
Strike 200 $
Maturity 21/06/2024 (19 Days)
Parity 10 : 1
Emission price 5.11
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 14.83
Lowest since issue 4.94

Company Profile

Stryker Corporation is one of the world's leaders in designing, manufacturing, and selling orthopedic equipments. Net sales break down by family of products as follows: - surgical equipments and neurotechnology products (57.5%): electric motorized surgical instruments, surgical navigation systems, endoscopy equipment, digital imaging systems, neurosurgery equipments, neurovascular devices, etc. The group also offers hospital beds, gurneys, stretchers, and emergency room equipment; - orthopedic implants (42.5%): joint prostheses, traumatology implants, micro-implants, orthopedic cement, orthobiology products, etc. The group also provides spinal implants. At the end of 2022, the group had 48 production sites worldwide. Net sales are distributed geographically as follows: the United States (73.9%), Europe/Middle East/Africa (12.7%), Asia/Pacific (10.2%) and other (3.2%).
Sector
-
More about the company

Ratings for Stryker Corporation

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Stryker Corporation

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
341.1 USD
Average target price
373.1 USD
Spread / Average Target
+9.38%
Consensus